Adapt Pharma has submitted an NDA for Narcan naloxone nasal spray for the treatment of opioid overdose to the FDA, the company has announced. In June 2015, Adapt said that it had initiated a rolling NDA submission.
Adapt Chairman and CEO Seamus Mulligan commented, “If FDA approved, Narcan Nasal Spray would allow for the administration of naloxone – the standard opioid overdose treatment – in an easy to use, needle-free, nasal spray formulation. We believe this would represent an important new tool to quickly respond to an opioid overdose emergency with this potentially life-saving medicine.”
Adapt licensed the product from Lightlake Therapeutics in December 2014. In February 2015, the FDA granted the naloxone nasal spray Fast Track Designation.
Read the Adapt Pharma press release.
